• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

两例肺炎性肌纤维母细胞瘤成功接受铂类-培美曲塞治疗：首例报告。

Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum-pemetrexed: The first report of two cases.

机构信息

Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Beijing, China.

Department of Pathology, Peking Union Medical College Hospital, Beijing, China.

出版信息

Thorac Cancer. 2020 Aug;11(8):2339-2342. doi: 10.1111/1759-7714.13520. Epub 2020 Jun 3.

DOI:10.1111/1759-7714.13520
PMID:32495499
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7396391/
Abstract

Pulmonary inflammatory myofibroblastic tumor (IMT) is a rare tumor. Here, we report two cases of pulmonary IMT successfully treated with platinum and pemetrexed. The results from this study suggest that platinum-pemetrexed might be an effective therapy in patients with IMT, but requires further investigation.

摘要

肺炎性肌纤维母细胞瘤（IMT）是一种罕见的肿瘤。在此，我们报告两例成功接受铂类和培美曲塞治疗的肺 IMT 病例。本研究结果表明，铂类-培美曲塞可能是 IMT 患者的一种有效治疗方法，但需要进一步研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10b1/7396391/ac8506668cd2/TCA-11-2339-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10b1/7396391/8fa133c03abf/TCA-11-2339-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10b1/7396391/ac8506668cd2/TCA-11-2339-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10b1/7396391/8fa133c03abf/TCA-11-2339-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/10b1/7396391/ac8506668cd2/TCA-11-2339-g002.jpg

相似文献

1
Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum-pemetrexed: The first report of two cases.两例肺炎性肌纤维母细胞瘤成功接受铂类-培美曲塞治疗：首例报告。
Thorac Cancer. 2020 Aug;11(8):2339-2342. doi: 10.1111/1759-7714.13520. Epub 2020 Jun 3.
2
Practice Patterns and Outcomes for Pemetrexed Plus Platinum Doublet as Neoadjuvant Chemotherapy in Adenocarcinomas of Lung: Looking Beyond the Usual Paradigm.培美曲塞联合铂类双药方案作为肺腺癌新辅助化疗的实践模式与疗效：突破常规模式
Clin Oncol (R Coll Radiol). 2018 Jan;30(1):23-29. doi: 10.1016/j.clon.2017.11.001. Epub 2017 Nov 24.
3
Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer.KEYNOTE-189 更新分析：帕博利珠单抗或安慰剂联合培美曲塞和铂类化疗用于未经治疗的转移性非鳞状非小细胞肺癌。
J Clin Oncol. 2020 May 10;38(14):1505-1517. doi: 10.1200/JCO.19.03136. Epub 2020 Mar 9.
4
Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations.培美曲塞单药与非培美曲塞铂类双药方案作为一线表皮生长因子受体（EGFR）酪氨酸激酶抑制剂治疗失败后的二线化疗用于EGFR突变的非小细胞肺癌患者。
Cancer Res Treat. 2015 Oct;47(4):630-7. doi: 10.4143/crt.2014.244. Epub 2015 Feb 16.
5
Pneumonectomy-Sparing NSAID Therapy for Pulmonary Inflammatory Myofibroblastic Tumor.保留肺叶的非甾体抗炎药治疗肺部炎性肌纤维母细胞瘤
J Thorac Oncol. 2015 Sep;10(9):e89-e90. doi: 10.1097/JTO.0000000000000574.
6
Anaplastic lymphoma kinase-negative pulmonary inflammatory myofibroblastic tumor with multiple metastases and its treatment by Apatinib: A case report.间变性淋巴瘤激酶阴性的伴有多发转移的肺部炎性肌纤维母细胞瘤及其阿帕替尼治疗：一例报告
Medicine (Baltimore). 2019 Dec;98(52):e18414. doi: 10.1097/MD.0000000000018414.
7
Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma.基于质谱的血清肽组学分析能够准确、可靠地预测晚期肺腺癌患者培美曲塞联合铂类化疗的疗效。
PLoS One. 2017 Jun 8;12(6):e0179000. doi: 10.1371/journal.pone.0179000. eCollection 2017.
8
Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer.KRAS 突变型晚期非鳞状非小细胞肺癌患者接受培美曲塞为基础或非培美曲塞为基础铂类双药化疗的临床结局。
Clin Transl Oncol. 2020 May;22(5):708-716. doi: 10.1007/s12094-019-02175-y. Epub 2019 Jul 22.
9
Inflammatory myofibroblastic tumor involving lung and brain in a 10-year-old boy: a case report.一名10岁男孩发生的累及肺和脑的炎性肌纤维母细胞瘤：病例报告
J Child Neurol. 2009 Oct;24(10):1302-6. doi: 10.1177/0883073809341270.
10
Bilateral multiple inflammatory myofibroblastic tumors of the lung successfully treated with corticosteroids.肺双侧多发炎性肌纤维母细胞瘤经皮质类固醇治疗成功。
Lung. 2011 Oct;189(5):433-5. doi: 10.1007/s00408-011-9314-3. Epub 2011 Aug 2.

引用本文的文献

1
Inflammatory myofibroblastic tumor of the lung: a comprehensive narrative review of clinical and therapeutic insights.肺炎性肌纤维母细胞瘤：临床与治疗见解的全面叙述性综述
Kardiochir Torakochirurgia Pol. 2025 Mar;22(1):32-43. doi: 10.5114/kitp.2025.148514. Epub 2025 Mar 14.
2
Chinese Expert Consensus on the Diagnosis and Treatment of Inflammatory Myofibroblastic Tumor.《中国炎性肌纤维母细胞瘤诊断与治疗专家共识》
Thorac Cancer. 2025 Mar;16(5):e70027. doi: 10.1111/1759-7714.70027.
3
Surgical treatment for lung metastasis of inflammatory myofibroblastic tumor of the lung: A case report.

本文引用的文献

1
How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature.在ALK易位阳性的炎性肌纤维母细胞瘤中，我们应该持续使用克唑替尼多长时间？克唑替尼治疗的长期完全缓解及文献综述。
J Oncol Pharm Pract. 2020 Jun;26(4):1011-1018. doi: 10.1177/1078155219879757. Epub 2019 Oct 15.
2
ALK inhibition in two emblematic cases of pediatric inflammatory myofibroblastic tumor: Efficacy and side effects.ALK 抑制在两个具有代表性的儿科炎症性肌纤维母细胞瘤病例中的应用：疗效和副作用。
Pediatr Blood Cancer. 2019 May;66(5):e27645. doi: 10.1002/pbc.27645. Epub 2019 Jan 29.
3
肺部炎性肌纤维母细胞瘤肺转移的外科治疗：一例报告。
Thorac Cancer. 2023 Jun;14(17):1644-1647. doi: 10.1111/1759-7714.14914. Epub 2023 May 5.
4
Surgical treatment outcomes of pulmonary inflammatory myofibroblastic tumors.肺炎性肌纤维母细胞瘤的外科治疗结果
Ann Thorac Med. 2022 Jan-Mar;17(1):44-50. doi: 10.4103/atm.atm_119_21. Epub 2022 Jan 14.
Clinical and Histopathologic Correlates and Management Strategies for Inflammatory Myofibroblastic tumor of the lung. A case series and review of the literature.
肺炎性肌纤维母细胞瘤的临床和组织病理学相关性及治疗策略。病例系列及文献复习。
Med Oncol. 2018 Jun 4;35(7):102. doi: 10.1007/s12032-018-1161-0.
4
Relapsed and unresectable inflammatory myofibroblastic tumor responded to chemotherapy: A case report and review of the literature.复发性及不可切除性炎性肌纤维母细胞瘤对化疗有反应：1例报告及文献复习
Mol Clin Oncol. 2017 Oct;7(4):521-524. doi: 10.3892/mco.2017.1383. Epub 2017 Aug 18.
5
Clinicopathological Study of 18 Cases of Inflammatory Myofibroblastic Tumors with Reference to ALK-1 Expression: 5-Year Experience in a Tertiary Care Center.18例炎症性肌纤维母细胞瘤的临床病理研究及ALK-1表达分析：三级医疗中心的5年经验
J Pathol Transl Med. 2017 May;51(3):255-263. doi: 10.4132/jptm.2017.01.12. Epub 2017 Apr 17.
6
Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.具有频繁间变性淋巴瘤激酶（ALK）和ROS1基因融合以及罕见新型RET重排的炎性肌纤维母细胞瘤的分子特征
Am J Surg Pathol. 2015 Jul;39(7):957-67. doi: 10.1097/PAS.0000000000000404.
7
Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.一项III期研究（PARAMOUNT）的长期和低级别安全性结果：培美曲塞维持治疗加最佳支持治疗与安慰剂加最佳支持治疗对比，用于晚期非鳞状非小细胞肺癌在接受培美曲塞加顺铂诱导治疗后立即进行。
Clin Lung Cancer. 2014 Nov;15(6):418-25. doi: 10.1016/j.cllc.2014.06.007. Epub 2014 Jun 21.
8
Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.炎性肌纤维母细胞瘤含有多种潜在可靶向的激酶融合。
Cancer Discov. 2014 Aug;4(8):889-95. doi: 10.1158/2159-8290.CD-14-0377. Epub 2014 May 29.